Wells Fargo & Company Alvotech Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Alvotech stock. As of the latest transaction made, Wells Fargo & Company holds 400 shares of ALVO stock, worth $5,032. This represents 0.0% of its overall portfolio holdings.
Number of Shares
400Holding current value
$5,032% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALVO
# of Institutions
43Shares Held
14.6MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA3.2MShares$40.2 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$34 Million5.53% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca1.93MShares$24.2 Million0.65% of portfolio
-
Morgan Stanley New York, NY1.48MShares$18.6 Million0.0% of portfolio
-
Littlejohn & CO LLC1.32MShares$16.6 Million7.91% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $3.13B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...